Stockscreener 앱 받기
8.78
0.69%
0.06
시간 외 거래:
8.78
Neogenomics Inc 주식(NEO)의 최신 뉴스
NeoGenomics stock hits 52-week low at $8.9 amid challenges By Investing.com - Investing.com South Africa
NeoGenomics stock hits 52-week low at $8.9 amid challenges - Investing.com
Testing & Diagnostics Services Stocks Q4 Recap: Benchmarking NeoGenomics (NASDAQ:NEO) - Yahoo Finance
NeoGenomics Announces Pricing of Public Offerings of Common Stock and Convertible Senior Notes - ACCESS Newswire
NeoGenomics Schedules its First Quarter Earnings Release for April 30, 2019 - ACCESS Newswire
NeoGenomics announces CEO transition - MSN
New CEO assumes role at NeoGenomics - Gulfshore Business
NeoGenomics appoints Tony Zook as CEO - Investing.com
NeoGenomics, Inc. Announces CEO Changes - MarketScreener
Tony Zook Assumes Role as Chief Executive Officer of NeoGenomics - BioSpace
NeoGenomics appoints Tony Zook as CEO By Investing.com - Investing.com Australia
NeoGenomics Appoints Tony Zook Chief Executive - MarketScreener
NeoGenomics' New CEO Zook Takes Over as Smith Retires - MarketWatch
Tony Zook Assumes Role As Chief Executive Officer Of Neogenomics - MarketScreener
Diagnostic Leader NeoGenomics Taps 30-Year Veteran to Drive Oncology Testing Growth - Stock Titan
Benchmark maintains Hold on Neogenomics stock, reiterates price target By Investing.com - Investing.com Canada
Where are the Opportunities in (NEO) - news.stocktradersdaily.com
3 Reasons to Sell NEO and 1 Stock to Buy Instead - Yahoo Finance
Piper Sandler maintains Neogenomics stock with $18 target - Investing.com
Piper Sandler maintains Neogenomics stock with $18 target By Investing.com - Investing.com UK
NeoGenomics elevates Warren Stone to President and COO By Investing.com - Investing.com Australia
NeoGenomics Promotes Warren Stone to President & COO - TipRanks
Fort Myers-based NeoGenomics names new COO - Gulfshore Business
Earnings call transcript: NeoGenomics Q4 2024 results disappoint despite EPS beat - Investing.com
NeoGenomics elevates Warren Stone to President and COO - Investing.com
NeoGenomics Names Warren Stone President, COO -March 18, 2025 at 08:09 am EDT - Marketscreener.com
NeoGenomics Appoints Warren Stone as President & Chief Operating Officer - Lelezard
NeoGenomics Appoints Warren Stone As President & Chief Operating Officer -March 18, 2025 at 07:10 am EDT - Marketscreener.com
Commit To Buy NeoGenomics At $8, Earn 19.6% Annualized Using Options - Nasdaq
NeoGenomics (NASDAQ:NEO) Stock Price Up 7.2%Here's What Happened - MarketBeat
SBI Securities Co. Ltd. Invests $26,000 in NeoGenomics, Inc. (NASDAQ:NEO) - Defense World
NeoGenomics at Barclays Healthcare: Strategic Focus on Innovation - Investing.com India
Bank of New York Mellon Corp Purchases 15,269 Shares of NeoGenomics, Inc. (NASDAQ:NEO) - Defense World
NeoGenomics, Inc. (NASDAQ:NEO) Receives $19.60 Average Target Price from Analysts - Defense World
NeoGenomics at Leerink Global Healthcare: Strategic Transition and Growth By Investing.com - Investing.com South Africa
(NEO) Technical Pivots with Risk Controls - news.stocktradersdaily.com
NeoGenomics at Leerink Global Healthcare: Strategic Transition and Growth - Investing.com
Fort Myers-based NeoGenomics expands cancer testing reach with acquisition - News-Press
Proficio Capital Partners LLC Invests $372,000 in NeoGenomics, Inc. (NASDAQ:NEO) - Defense World
BTIG maintains $17 target on Neogenomics stock post-acquisition By Investing.com - Investing.com UK
NeoGenomics Acquires Pathline -March 10, 2025 at 08:13 am EDT - Marketscreener.com
NeoGenomics Expands Oncology Testing Reach in the Northeast with Acquisition of Pathline - BioSpace
NeoGenomics expands with Pathline acquisition - Investing.com India
NeoGenomics expands with Pathline acquisition By Investing.com - Investing.com South Africa
NeoGenomics Expands Oncology Testing Reach In The Northeast With Acquisition Of Pathline - Marketscreener.com
Smartleaf Asset Management LLC Has $70,000 Position in NeoGenomics, Inc. (NASDAQ:NEO) - Defense World
NeoGenomics Launches Immuno-Oncology Companion Diagnostic Test for Triple Negative Breast Cancer in Conjunction with FDA Approval for TECENTRIQ(R) - ACCESS Newswire
NeoGenomics, Inc.'s (NASDAQ:NEO) Stock Retreats 28% But Revenues Haven't Escaped The Attention Of Investors - Simply Wall St
NeoGenomics, Inc. to Host Earnings Call - ACCESS Newswire
NeoGenomics price target lowered to $17 from $18 at BTIG - MSN
NeoGenomics at TD Cowen Conference: CEO Transition and Growth Plans By Investing.com - Investing.com UK
NeoGenomics, Inc. (NASDAQ:NEO) Shares Sold by Truist Financial Corp - Defense World
3.49%
자본화:
|
볼륨(24시간):